Spyre Therapeutics (SYRE) Other Non Operating Income (2015 - 2026)
Spyre Therapeutics (SYRE) posted Other Non Operating Income of -$30.4 million for Q1 2026, down 142.93% on a QoQ basis from -$12.5 million in Q4 2025, and down 1428.04% year-over-year from $2.3 million in Q1 2025.
Spyre Therapeutics (SYRE) Other Non Operating Income (2015 - 2026) Analysis & Trends
Spyre Therapeutics' Other Non Operating Income history runs 12 years deep, the most recent figure standing at -$30.4 million for Q1 2026.
- Quarterly Other Non Operating Income fell 1428.04% year-over-year to -$30.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$3.2 million (up 82.24% YoY) and the FY2025 annual result came in at $29.5 million, up 242.22% from the prior year.
- Other Non Operating Income was -$30.4 million for Q1 2026 at Spyre Therapeutics, down from -$12.5 million in the prior quarter.
- Across five years, Other Non Operating Income topped out at $40.3 million in Q3 2025 and bottomed at -$30.4 million in Q1 2026.
- A 5-year average of -$2.4 million and a median of -$72000.0 in 2023 frame the typical range for Other Non Operating Income.
- Peak annual rise in Other Non Operating Income reached 9658.33% in 2023, while the deepest fall reached 66750.0% in 2023.
- Spyre Therapeutics' Other Non Operating Income stood at -$32000.0 in 2022, then slumped by 66750.0% to -$21.4 million in 2023, then jumped by 96.18% to -$818000.0 in 2024, then sank by 1427.75% to -$12.5 million in 2025, then slumped by 142.93% to -$30.4 million in 2026.
- Business Quant data shows SYRE's Other Non Operating Income at -$30.4 million in Q1 2026, -$12.5 million in Q4 2025, and $40.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Spyre Therapeutics | 259.59 Mn | 259.59 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -30.36 Mn |
| Dec 31, 2025 | -12.50 Mn |
| Sep 30, 2025 | 40.33 Mn |
| Jun 30, 2025 | -656,000.00 |
| Mar 31, 2025 | 2.29 Mn |
| Dec 31, 2024 | -818,000.00 |
| Sep 30, 2024 | -18.80 Mn |
| Jun 30, 2024 | -610,000.00 |
| Mar 31, 2024 | -483,000.00 |
| Dec 31, 2023 | -21.39 Mn |
| Sep 30, 2023 | 2.34 Mn |
| Jun 30, 2023 | -8,000.00 |
| Mar 31, 2023 | -72,000.00 |
| Dec 31, 2022 | -32,000.00 |
| Sep 30, 2022 | 24,000.00 |
| Jun 30, 2022 | 5,000.00 |
| Mar 31, 2022 | -30,000.00 |
| Dec 31, 2021 | -15,000.00 |
| Sep 30, 2021 | -24,000.00 |
| Jun 30, 2021 | -52,000.00 |